Research for clinical application of gene therapy for head and neck cancer

头颈癌基因治疗的临床应用研究

基本信息

  • 批准号:
    14370543
  • 负责人:
  • 金额:
    $ 8.77万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2002
  • 资助国家:
    日本
  • 起止时间:
    2002 至 2005
  • 项目状态:
    已结题

项目摘要

Objective : To teat the oncolytic activity of COX2-promoter based conditional replication-selective adenovirus vector for squamous cell carcinoma cells of head and neck.Subjects : A conditional replication-selective adenovirus vector in which the expression of Ela, required for viral replication, is controlled by the COX-2 promoter, Ad-COX2-Ela, was generated. Its oncolytic activity according to the levels of COX-2 and CAR (Coxsackie and adenovirus receptor) expression was tested in a series of human head and neck squamous cell carcinoma cell lines.ResultsThe respective COX-2 mRNA expression ratios of KB, H891, T891, T892, and L871 were 1.5, 60, 1, 14.6, and 1.3. The corresponding CAR mRNA expression ratios were 1, 1, 5, 4, and 3. In vitro assays showed significant growth suppression of cancer cell lines with strong expressions of COX-2. In addition, Ad-COX2-Ela showed significant growth suppression of COX-2 expressing tumors in vivo model.CenclusionsIn this study, we demonstrated the possibility of oncolytic therapy using the COX-2 promoter based conditional replication-selective adenovirus for head dnd neck squamous cell carcinoma expressing COX-2.
目的:目的:研究考克斯-2启动子调控的条件复制选择性腺病毒载体(Ad-COX-2-Ela)对头颈部鳞癌细胞的杀伤活性。其溶瘤活性根据考克斯-2和CAR(科萨基和腺病毒受体)的表达水平进行了测试,在一系列的人头颈部鳞状细胞癌细胞line.ResultsThe相应的考克斯-2 mRNA表达率KB,H891,T891,T892,和L 871分别为1.5,60,1,14.6,和1.3。相应的CAR mRNA表达比率为1、1、5、4和3。体外试验显示,考克斯-2强表达的癌细胞系的生长受到显著抑制。此外,Ad-COX 2-Ela对表达考克斯-2的肿瘤有明显的生长抑制作用,提示利用基于考克斯-2启动子的条件复制选择性腺病毒治疗表达考克斯-2的头颈部鳞状细胞癌是可行的。

项目成果

期刊论文数量(46)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas
Partial laryngectomy to treat early glottic cancer after failure of radiation therapy
Intraductal papilloma arising from Stenson's duct
源自斯滕森导管的导管内乳头状瘤
A replication-selective adenoviral vector for head and neck cancers
Adenovirsu-mediated gene transfer in olfactory epithelium and olfactgory bulb : a long-term study
腺病毒介导的嗅上皮和嗅球基因转移:一项长期研究
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Doi K;Nibu K;Ishida H;Okada H;Terashima T
  • 通讯作者:
    Terashima T
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NIBU Ken-ichi其他文献

NIBU Ken-ichi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NIBU Ken-ichi', 18)}}的其他基金

Metabolome analysis of head and neck cancer to identify the clinical markers
头颈癌的代谢组分析以确定临床标志物
  • 批准号:
    23659795
  • 财政年份:
    2011
  • 资助金额:
    $ 8.77万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Genetherapy for Head and Neck Cancer using carrier cell-based delivery of replication-selective adenoviral vector
使用基于载体细胞的复制选择性腺病毒载体递送进行头颈癌基因治疗
  • 批准号:
    21390462
  • 财政年份:
    2009
  • 资助金额:
    $ 8.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Study on molecular biological mechanism of regeneration of olfactory receptor neurons and regeneration medicine of olfaction
嗅觉受体神经元再生的分子生物学机制及嗅觉再生药物研究
  • 批准号:
    18390458
  • 财政年份:
    2006
  • 资助金额:
    $ 8.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The roles of ret/PTC fusion genes in thyroid papillary carcinoma
ret/PTC融合基因在甲状腺乳头状癌中的作用
  • 批准号:
    11671671
  • 财政年份:
    1999
  • 资助金额:
    $ 8.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Gene therapy for head and neck cancer using replication-selective adenoviral vector
使用复制选择性腺病毒载体治疗头颈癌
  • 批准号:
    25670717
  • 财政年份:
    2013
  • 资助金额:
    $ 8.77万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Development of gene therapy for epidermolysis bullosa with adenoviral vector by homologous recombination of mutant gene in mesenchymal stem cells.
通过间充质干细胞中突变基因的同源重组,开发腺病毒载体治疗大疱性表皮松解症的基因疗法。
  • 批准号:
    23791267
  • 财政年份:
    2011
  • 资助金额:
    $ 8.77万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
The Establishment of Gene Therapy with and Gene Expression Regulation of Adenoviral Vector Serotype 35
35型腺病毒载体基因治疗的建立及基因表达调控
  • 批准号:
    21592242
  • 财政年份:
    2009
  • 资助金额:
    $ 8.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer
用于卵巢癌基因治疗的卵巢选择性腺病毒载体
  • 批准号:
    6667427
  • 财政年份:
    2002
  • 资助金额:
    $ 8.77万
  • 项目类别:
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer
用于卵巢癌基因治疗的卵巢选择性腺病毒载体
  • 批准号:
    6504974
  • 财政年份:
    2001
  • 资助金额:
    $ 8.77万
  • 项目类别:
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer
用于卵巢癌基因治疗的卵巢选择性腺病毒载体
  • 批准号:
    6352804
  • 财政年份:
    2000
  • 资助金额:
    $ 8.77万
  • 项目类别:
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer
用于卵巢癌基因治疗的卵巢选择性腺病毒载体
  • 批准号:
    6230168
  • 财政年份:
    1999
  • 资助金额:
    $ 8.77万
  • 项目类别:
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer
用于卵巢癌基因治疗的卵巢选择性腺病毒载体
  • 批准号:
    6323317
  • 财政年份:
    1999
  • 资助金额:
    $ 8.77万
  • 项目类别:
Research for gene therapy of α-glucosidase deficiency using adenoviral vector
腺病毒载体治疗α-葡萄糖苷酶缺乏症的基因治疗研究
  • 批准号:
    09670687
  • 财政年份:
    1997
  • 资助金额:
    $ 8.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Gene Therapy for Colon Cancer with Adenoviral Vector Expressing Tumor Suppressor p53 Gene
表达肿瘤抑制p53基因的腺病毒载体对结肠癌的基因治疗
  • 批准号:
    07671393
  • 财政年份:
    1995
  • 资助金额:
    $ 8.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了